Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Total Non-Current Liabilities (2021 - 2025)

Kiniksa Pharmaceuticals International's Total Non-Current Liabilities history spans 5 years, with the latest figure at $177.5 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 26.52% year-over-year to $177.5 million; the TTM value through Dec 2025 reached $177.5 million, up 26.52%, while the annual FY2025 figure was $177.5 million, 26.52% up from the prior year.
  • Total Non-Current Liabilities reached $177.5 million in Q4 2025 per KNSA's latest filing, up from $162.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $177.5 million in Q4 2025 to a low of $37.9 million in Q3 2021.
  • Average Total Non-Current Liabilities over 5 years is $89.5 million, with a median of $75.1 million recorded in 2022.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 95.45% in 2022, then fell 21.05% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $47.5 million in 2021, then rose by 29.88% to $61.7 million in 2022, then soared by 38.81% to $85.6 million in 2023, then soared by 63.85% to $140.3 million in 2024, then increased by 26.52% to $177.5 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Total Non-Current Liabilities are $177.5 million (Q4 2025), $162.4 million (Q3 2025), and $156.9 million (Q2 2025).